Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | CHAT | P28329 | 1/20 | 0.34 |
| ▸ | ATIC | P31939 | 1/20 | 0.34 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.34 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024402 | 0.88 | CYP1A2 (0.43) | CYP1A2TTRKCNA5IDO1SNCA | |
| SCHEMBL9626477 | 0.81 | TTR (0.50) | CYP1A2TTRIDO1SNCANSD2 | |
| SCHEMBL13223261 | 0.76 | MAPT (0.47) | CYP1A2TTRIDO1EDNRASLC6A9 | |
| SCHEMBL5016478 | 0.76 | CNR1 (0.52) | CYP1A2TTRIDO1 | |
| SCHEMBL5022978 | 0.76 | CNR1 (0.49) | CYP1A2TTRIDO1 | |
| SCHEMBL14159082 | 0.76 | CYP1A2 (0.51) | CYP1A2TTR | |
| SCHEMBL12221061 | 0.74 | TTR (0.46) | CYP1A2TTRIDO1SNCANSD2 | |
| SCHEMBL7757566 | 0.74 | TTR (0.56) | CYP1A2TTRIDO1SNCANSD2 | |
| SCHEMBL14012469 | 0.74 | CYP1A2 (0.46) | CYP1A2TTRIDO1SNCANSD2 | |
| SCHEMBL12041809 | 0.73 | TTR (0.45) | CYP1A2TTRIDO1SNCANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365223-B2 | Method for selective targeting of apoptotic cells and small molecule ligands used thereof | NST NEUROSURVIVAL TECHNOLOGIES LTD (IL) | 2008-04-29 | — | — | US | disclosed |
| US-20060160901-A1 | Method for selective targeting of apoptotic cells and small molecule ligands used thereof | APOSENSE LTD. (IL) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160901-A1 | Method for selective targeting of apoptotic cells and small molecule ligands used thereof | BAD, BAX, CASP3 | CYP1A2 4638/4885TTR 4380/4885KCNA5 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.